Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies

Experimental Hematology

Volumn 38, Issue 12, 2010, Pages 1241-1250

  Blaise, Didier ^a,b   Farnault, Laure ^a   Faucher, Catherine ^a   Marchetti, Nicholas ^a,c   Fürst, Sabine ^a   El Cheikh, Jean ^a   Ladaique, Patrick ^a   Vey, Norbert ^a   Bouabdallah, Reda ^a   Stoppa, Anne Marie ^a   Lemarie, Claude ^a   Calmels, Boris ^a   Prebet, Thomas ^a   Castagna, Luca ^a   Chabannon, Christian ^a,b   Mohty, Mohamad ^a,d   Esterni, Benjamin ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c Hospital Marciel   (Uruguay)

^d NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BUSULFAN; CD34 ANTIGEN; COTRIMOXAZOLE; CYCLOSPORIN A; FLUDARABINE; FLUDARABINE PHOSPHATE; HEPARIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY; VALACICLOVIR;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CANCER CONTROL; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC GRANULOCYTIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEALTH STATUS; HEMATOLOGIC MALIGNANCY; HERPES SIMPLEX; HLA MATCHING; HODGKIN DISEASE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERTHES DISEASE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; BUSULFAN; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; TRANSPLANTATION CONDITIONING; VIDARABINE;

ORYCTOLAGUS CUNICULUS;

EID: 78549271458     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.08.012     Document Type: Article

References (41)

1. Storb R. Allogeneic hematopoietic stem cell transplantation-yesterday, today, and tomorrow. Exp Hematol 2003, 31:1-10.
2. Vriesendorp H.M. Aims of conditioning. Exp Hematol 2003, 31:844-854.
3. Thomas E., Storb R., Clift R., et al. Bone marrow transplantation. N Engl J Med 1975, 292:832-843. 895-902.
4. Holler E., Kolb H.J., Moller A., et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990, 75:1011-1016.
5. Ferrara J.L., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
6. Storb R., Yu C., Wagner J.L., et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997, 89:3048-3054.
7. Georges G.E., Storb R. Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation. Int J Hematol 2003, 77:3-14.
8. Giralt S., Estey E., Albitar M., et al. Engrafment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997, 89:4531-4536.
9. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756-763.
10. Gratwohl A., Baldomero H., Schwendener A., et al. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplant 2009, 43:275-291.
11. Mohty M., Bay J.O., Faucher C., et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003, 102:470-476.
12. Blaise D., Vey N., Faucher C., Mohty M. Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 2007, 92:533-541.
13. Ivanov V., Faucher C., Mohty M., et al. Decreased RBCTs after reduced intensity conditioning allogeneic stem cell transplantation: predictive value of prior Hb level. Transfusion 2004, 44:501-508.
14. Prebet T., Ladaique P., Ferrando M., et al. Platelet recovery and transfusion needs after reduced intensity conditioning allogeneic peripheral blood stem cell transplantation. Exp Hematol 2010, 38:55-60.
15. Olivero S., Alario T., Ladaique P., et al. CD34+ cell enumeration in peripheral blood and apheresis samples, using two laboratory diagnostic kits or an institutional protocol. Bone Marrow Transplant 1999, 23:387-394.
16. Gutensohn K., Carrero I., Krueger W., et al. Semi-automated flow cytometric analysis of CD34-expressing hematopoietic cells in peripheral blood progenitor cell apheresis products. Transfusion 1999, 39:1220-1226.
17. Keeney M., Chin-Yee I., Weir K., Popma J., Nayar R., Sutherland D.R. Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. International Society of Hematotherapy and Graft Engineering. Cytometry 1998, 34:61-70.
18. Sutherland D.R., Anderson L., Keeney M., Nayar R., Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996, 5:213-226.
19. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
20. Gratwohl A., Stern M., Brand R., et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009, 115:4715-4726.
21. Mohty M., Avinens O., Faucher C., Viens P., Blaise D., Eliaou J.F. Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. Haematologica 2007, 92:1004-1006.
22. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients from HL-A-matched sibling donors. Transplantation 1974, 18:295-304.
23. Cox D. Regression models and life tables. J R Stat Soc (B) 1972, 34:187-220.
24. Michallet M., Bilger K., Garban F., et al. Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome. J Clin Oncol 2001, 19:3340-3349.
25. Martino R., Iacobelli S., Brand R., et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006, 108:836-846.
26. Michallet M., Le Q.H., Mohty M., et al. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Exp Hematol 2008, 36:535-544.
27. Aoudjhane M., Labopin M., Gorin N.C., et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005, 19:2304-2312.
28. Sureda A., Robinson S., Canals C., et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008, 26:455-462.
29. Ringden O., Horowitz M.M., Gale R.P., et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA 1993, 270:57-60.
30. Wallen H., Gooley T.A., Deeg H.J., et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol 2005, 23:3439-3446.
31. Baron F., Maris M.B., Sandmaier B.M., et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005, 23:1993-2003.
32. Sorror M.L., Maris M.B., Storer B., et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004, 104:961-968.
33. Faucher C., Mohty M., Vey N., et al. Bone marrow as stem cell source for allogeneic HLA-identical sibling transplantation following reduced-intensity preparative regimen. Exp Hematol 2003, 31:873-880.
34. Mohty M., Mohty A.M., Blaise D., et al. Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen. Bone Marrow Transplant 2004, 33:839-846.
35. Blaise D.P., Michel Boiron J., Faucher C., et al. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer 2005, 104:1931-1938.
36. de Lavallade H., Mohty M., El-Cheikh J., et al. Reduced-intensity conditioning allogeneic stem cell transplantation for patients with chemoresistant or relapsed follicular lymphoma. Br J Haematol 2006, 135:408-410.
37. Mohty M., de Lavallade H., El-Cheikh J., et al. Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a 'donor' versus 'no donor' comparison. Leukemia 2009, 23:194-196.
38. Robinet E., Lapierre V., Tayebi H., Kuentz M., Blaise D., Tiberghien P. Blood versus marrow hematopoietic allogeneic graft. Transfus Apheresis Sci 2003, 29:53-59.
39. Mohty M., Bilger K., Jourdan E., et al. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia 2003, 17:869-875.
40. Zaucha J.M., Gooley T., Bensinger W.I., et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001, 98:3221-3227.
41. Baron F., Maris M.B., Storer B.E., et al. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia 2005, 19:822-828.